BRIM Biotechnology, Inc. (TPE:6885)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
25.85
-0.25 (-0.96%)
At close: Mar 6, 2026
-10.86%
Market Cap 3.32B
Revenue (ttm) 3.17M
Net Income (ttm) -387.70M
Shares Out 133.21M
EPS (ttm) -3.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 294,150
Average Volume 553,037
Open 26.25
Previous Close 26.10
Day's Range 25.75 - 26.25
52-Week Range 20.05 - 41.30
Beta 1.03
RSI 30.84
Earnings Date Mar 17, 2026

About BRIM Biotechnology

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company’s lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that ha... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 32
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6885
Full Company Profile

Financial Performance

In 2024, BRIM Biotechnology's revenue was 333,000, an increase of 270.00% compared to the previous year's 90,000. Losses were -315.47 million, -54.15% less than in 2023.

Financial Statements

News

There is no news available yet.